Please login to the form below

Not currently logged in
Email:
Password:

Former GSK exec joins PureTech Health

Dr Atul Pande becomes chief medical officer

PureTech Health Dr Atul PandeBoston, US-based PureTech Health has appointed Dr Atul Pande as its new chief medical officer, responsible for the firm's pipeline in immune, nervous and gastro-intestinal systems.

Dr Pande was formerly senior vice president and head of neuroscience at GlaxoSmithKline, where he also served as a senior advisor in its R&D division.

Prior to this, he was chief medical officer at Cenerx Biopharma and brings further R&D leadership experience from Pfizer, where he served as vice president for neurosciences.

Dr Pande currently serves on the board of directors for Karuna Pharmaceuticals - part of PureTech Health - as well as Axovant Sciences, Autifony Therapeutics, and Cennerv Pharma's scientific advisory board.

Daphne Zohar, chief executive officer of PureTech Health, said: “We are excited to work more closely with Atul and to have access to his drug development expertise across PureTech Health's pipeline.

“Atul is a seasoned drug development veteran who will help to shepherd our advancing pipeline through mid- and late-stage clinical trials while ensuring that synergies are leveraged across our platforms.”

27th February 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...